103259-35-4

Basic information

• Product Name: ethyl 5-aMino-1H-pyrazole-4-carboxylate
• Synonyms: Ethyl 5-amino-1H-pyrazole-4-carboxylate AldrichCPR
• CAS NO: 103259-35-4
• Molecular Formula: C6H9N3O2
• Molecular Weight: 155
• EINECS: -0
• Mol File: 103259-35-4.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 349.2 °C at 760 mmHg
• Flash Point: 165 °C
• Appearance: /
• Density: 1.318 g/cm³
• CAS DataBase Reference: ethyl 5-aMino-1H-pyrazole-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 5-aMino-1H-pyrazole-4-carboxylate(103259-35-4)
• EPA Substance Registry System: ethyl 5-aMino-1H-pyrazole-4-carboxylate(103259-35-4)

Safety Data

• Hazard Codes: Xi
• Statements: 43
• Safety Statements: 36/37
• Hazardous Substances Data: 103259-35-4(Hazardous Substances Data)

Usage

General Description

Ethyl 5-amino-1H-pyrazole-4-carboxylate is a chemical compound with the molecular formula C7H10N3O2. It belongs to the class of compounds known as pyrazoles, which comprise a five-membered aromatic ring with two nitrogen atoms. This chemical is usually used in research and development and is not applied typically for household or commercial use. The properties of this compound, like its boiling point, melting point, and density, are contingent on multiple factors, including its purity, pressure, and temperature. This substance is light in nature, and it is highly recommended to avoid direct contact, ingestion, or inhalation to steer clear from potential health risks.

Upstream product

• 42466-67-1 ethyl (ethoxymethylene)cyanoacetate 
• 64-17-5 ethanol 
• 7803-57-8 hydrazine hydrate 
• 94-05-3 2-cyano-3-ethoxyacrylic acid ethyl ester 
• 94-05-3 ethyl (ethoxymethylene)cyanoacetate 
• 105-56-6 ethyl 2-cyanoacetate 
• 6630-64-4 ethyl 2-cyano-3-morpholin-4-ylacrylate 
• 144918-37-6 (E)-ethyl 2-cyano-3-ethoxyacrylate 

Downstream Products

• 104556-86-7 3-ethoxycarbonylpyrazolo<1,5-a>pyrimidin-7-one 
• 116519-76-7 3-[1-Dimethylamino-eth-(E)-ylideneamino]-1H-pyrazole-4-carboxylic acid ethyl ester 
• 126314-61-2 3-Amino-1-(O,O-diphenylthiophosphoryl)-4-ethoxycarbonyl-pyrazole 
• 126314-71-4 Phenoxymethylthiophosphonate Salt of 3-Amino-4-ethoxycarbonylpyrazole 
• 116519-73-4 3-(Dimethylamino-methyleneamino)-1H-pyrazole-4-carboxylic acid ethyl ester 
• 83451-22-3 1-(2-Nitrobenzenesulfonyl)-4-carbethoxy-3-aminopyrazole 
• 83451-27-8 1-(2-Nitrobenzenesulfonyl)-4-carbethoxy-5-aminopyrazole 
• 31055-19-3 3-formylamino-1H-pyrazole-4-carboxylic acid ethyl ester 
• 134791-37-0 4,5-Dihydro-6-methyl-4-oxopyrazolo<3,4-d>pyrimidin 
• 83451-23-4 1-(2-Nitrobenzoyl)-4-carbethoxy-3-aminopyrazole 
• 83451-28-9 1-(2-Nitrobenzoyl)-4-carbethoxy-5-aminopyrazole 
• 624720-40-7 3-amino-1-hydroxycarbamoylmethyl-1H-pyrazole-4-carboxylic acid ethyl ester 
• 161886-55-1 4-(2'-Cyano-biphenyl-4-ylmethyl)-6-cyclopropyl-7-oxo-4,7-dihydro-pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester 
• 161886-52-8 4-(2'-Cyano-biphenyl-4-ylmethyl)-7-oxo-6-propyl-4,7-dihydro-pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester 

Relevant articles and documents

Fused 3-hydroxy-3-trifluoromethylpyrazoles inhibit mutant huntingtin toxicity

Here, we describe the selection and optimization of a chemical series active in both a full-length and a fragment-based Huntington's disease (HD) assay. Twenty-four thousand small molecules were screened in a phenotypic HD assay, identifying a series of compounds bearing a 3-hydroxy-3- trifluoromethylpyrazole moiety as able to revert the toxicity induced by full-length mutant Htt by up to 50%. A chemical exploration around the series led to the identification of compound 4f, which demonstrated to be active in a Htt171-82Q rat primary striatal neuron assay and a PC12-Exon-1 based assay. This compound was selected for testing in R6/2 mice, in which it was well-tolerated and showed a positive effect on body weight and a positive trend in preventing ventricular volume enlargment. These studies provide strong rationale for further testing the potential benefits of 3-hydroxy-3-trifluoromethylpyrazoles in treating HD.

Discovery and structure ? activity relationship exploration of pyrazolo[1,5-a]pyrimidine derivatives as potent FLT3-ITD inhibitors

Internal tandem duplications of FLT3 (FLT3-ITD) occur in approximately 25% of all acute myeloid leukemia (AML) cases and confer a poor prognosis. Optimization of the screening hit 1 from our in-house compound library led to the discovery of a series of pyrazolo[1,5-a]pyrimidine derivatives as potent and selective FLT3-ITD inhibitors. Compounds 17 and 19 displayed potent FLT3-ITD activities both with IC50 values of 0.4 nM and excellent antiproliferative activities against AML cell lines. Especially, compounds 17 and 19 inhibited the quizartinib resistance- conferring mutations, FLT3D835Y, both with IC50 values of 0.3 nM. Moreover, western blot analysis indicated that compounds 17 and 19 potently inhibited the phosphorylation of FLT3 and attenuated downstream signaling in AML cells. These results indicated that pyrazolo[1,5-a]pyrimidine derivatives could be promising FLT3-ITD inhibitors for the treatment AML.

A class of FLT3 kinase inhibitors, preparation and application thereof

The invention relates to a class of FLT3 kinase inhibitors, preparation and application thereof, wherein specifically the compound has a structure represented by a formula (I), and all groups and substituents are defined in the specification. The invention also discloses a preparation method of the compound, and application of the compound in inhibition of FLT3.